We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Fortress Biotech Inc (FBIO) USD0.001

Sell:$1.68 Buy:$1.72 Change: No change
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:$1.68
Buy:$1.72
Change: No change
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:$1.68
Buy:$1.72
Change: No change
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

Contact details

Address:
1111 KANE CONCOURSE, SUITE 301
BAY HARBOR ISLANDS
33154
United States
Telephone:
+1 (781) 6524500
Website:
https://www.fortressbiotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FBIO
ISIN:
US34960Q3074
Market cap:
$34.43 million
Shares in issue:
19.23 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Lindsay Rosenwald
    Executive Chairman of the Board, President, Chief Executive Officer
  • David Jin
    Chief Financial Officer, Corporate Secretary
  • Michael Weiss
    Executive Vice Chairman - Strategic Development, Director
  • George Avgerinos
    Senior Vice President - Biologics Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.